Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2026-02-25 @ 4:57 PM
Study NCT ID:
NCT02431260
Status:
TERMINATED
Last Update Posted:
2019-06-14
First Post:
2015-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Sponsor:
Incyte Corporation
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Solid Tumors and Hematologic Malignancy | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | solid tumor | View |
| None | lymphoma | View |
| None | BET bromodomain inhibitor | View |
| None | BRD | View |
| None | Diffuse large B-cell lymphoma (DLBCL) | View |
| None | Burkitt's lymphoma | View |
| None | c-MYC | View |
| None | colorectal cancer | View |
| None | Non-small cell lung cancer | View |
| None | Pancreatic adenocarcinoma | View |
| None | castration-resistant prostate cancer | View |
| None | breast cancer | View |
| None | NUT midline carcinoma | View |
| None | leukemia | View |
| None | acute myeloid leukemia (AML) | View |
| None | myelodysplastic syndrome (MDS) | View |
| None | myeloproliferative neoplasms | View |
| None | myelofibrosis (MF) | View |
| None | multiple myeloma (MM) | View |
| None | MDS/MPN | View |